8-K filed Oct 30, 2025
Edwards Lifesciences authorizes $2.1B for stock buybacks
“The Edwards Lifesciences Board of Directors has approved an increase in the company’s share repurchase authorization, which now totals approximately $2.1 billion.”
From Edwards Lifesciences’s 8-K filed Oct 30, 2025 · read the filing · all documents
How big is it?
Edwards Lifesciences bought back $1.2B of stock in the twelve months to Jun 30, 2026. At that pace, $2.1B covers about 1.7 years of buybacks.
The amount equals 146% of its free cash flow over the same twelve months ($1.4B).
Its diluted share count is down 1.8% from a year earlier.
An authorization is permission, not a promise: the company can buy less, more slowly, or not at all, and usually doesn't have to say when it buys.
Show as table
| Period | Value |
|---|---|
| Q3 '23 | $174.4M |
| Q4 '23 | $448.4M |
| Q1 '24 | $200,000 |
| Q2 '24 | $158.1M |
| Q3 '24 | $901M |
| Q4 '24 | $100.1M |
| Q1 '25 | $258.6M |
| Q2 '25 | $5.5M |
| Q3 '25 | $588.7M |
| Q4 '25 | $40.6M |
| Q1 '26 | $421.8M |
| Q2 '26 | $153.3M |